PI
NBIX icon

Putnam Investments’s Neurocrine Biosciences NBIX Stock Holding History

Putnam Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$3.75M Sell
28,436
-799
-3% -$92K ﹤0.01% 516
2023
Q3 		$3.29M Buy
+29,235
New +$3.08M 0.01% 558
2021
Q2 		– Sell
-23,931
Closed -$2.33M – 823
2021
Q1 		$2.33M Sell
23,931
-1,156
-5% -$121K ﹤0.01% 661
2020
Q4 		$2.4M Buy
25,087
+3,945
+19% +$381K ﹤0.01% 640
2020
Q3 		$2.03M Buy
21,142
+3,764
+22% +$435K ﹤0.01% 652
2020
Q2 		$2.12M Buy
+17,378
New +$1.92M ﹤0.01% 666
2017
Q3 		– Sell
-196,174
Closed -$9.02M – 1162
2017
Q2 		$9.02M Buy
196,174
+173,947
+783% +$8.44M 0.02% 388
2017
Q1 		$962K Sell
22,227
-5,121
-19% -$219K ﹤0.01% 1007
2016
Q4 		$1.06M Buy
27,348
+2,222
+9% +$101K ﹤0.01% 994
2016
Q3 		$1.27M Sell
25,126
-15,729
-38% -$783K ﹤0.01% 965
2016
Q2 		$1.86M Sell
40,855
-38,556
-49% -$1.78M ﹤0.01% 953
2016
Q1 		$3.14M Buy
79,411
+1,682
+2% +$66.7K 0.01% 819
2015
Q4 		$4.4M Sell
77,729
-1,266
-2% -$64.3K 0.01% 710
2015
Q3 		$3.14M Buy
78,995
+39,940
+102% +$1.93M 0.01% 842
2015
Q2 		$1.86M Buy
+39,055
New +$1.66M ﹤0.01% 1083
2013
Q3 		– Sell
-158,300
Closed -$2.12M – 1484
2013
Q2 		$2.12M Buy
+158,300
New +$1.94M 0.01% 1035

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments's NBIX Position: Q4 2023 in Review

Putnam Investments reduced its Neurocrine Biosciences (NBIX) stake by 2.7% in Q4 2023, selling an estimated $92K and leaving 28,436 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #516.

Putnam Investments first reported a position in NBIX in Q2 2013 and has held it in 16 quarters since. The position peaked at $9.02M in Q2 2017. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Putnam Investments held 28,436 shares of Neurocrine Biosciences worth $3.75M as of Q4 2023.
  • Putnam Investments sold 799 Neurocrine Biosciences shares in Q4 2023, an estimated $92K.
  • Neurocrine Biosciences made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #516 holding.
  • Putnam Investments first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 16 quarters since.
  • Putnam Investments's Neurocrine Biosciences position peaked at $9.02M in Q2 2017.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.